Jeanie Chui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeanie Chui has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Denis Wakefield
School of Medical Sciences, University of New South Wales, Sydney, Australia
10 shared publicationsMinas T. Coroneo
6 shared publications- Nick Di Girolamo
School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia
6 shared publications Nick Di Girolamo
From the Inflammatory Diseases Research Unit, Department of Pathology, School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
3 shared publications- Peter McCluskey
Save Sight Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
3 shared publications - Andrew R. Lloyd
The Kirby Institute, University of New South Wales, Sydney, Australia
2 shared publications
Latest Publications
- 1 October 2018
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 26 (9) , e91-e92
Loss of BAP1 Expression Occurs Rarely to Never in Colorectal Adenocarcinoma
- 1 October 2018
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 26 (9) , e91-e92
Loss of BAP1 Expression Occurs Rarely to Never in Colorectal Adenocarcinoma
- 1 December 2015
- Published by Wolters Kluwer Health in Cornea
- Vol. 34 (12) , 1560-1563
Significance of Fuchs Flecks in Patients With Pterygium/Pinguecula
Fuchs flecks (FFs) have been previously identified at the leading edge of pterygia and may represent collections of epithelial stem-like cells that give rise to this condition. This study aims to evaluate the clinical significance of FFs in patients with ocular surface disorders, such as pterygium and pinguecula, by in vivo confocal microscopy (IVCM). This study is a Single-center, retrospective, observational case series of 40 eyes from 20 patients with clinical diagnoses of pinguecula or pterygium, or both. IVCM (Rostock Cornea Module; Heidelberg Engineering, Heidelberg, Germany) was performed on patients with pinguecula or pterygium, or both. The presence of FFs on the ocular surface of patients with pterygium and pinguecula was assessed by IVCM and subsequently documented. FFs were present in 24 of 30 eyes (80.0%) in paired macroscopically normal nasal or limbal regions, 19 of 20 (95.0%) in pinguecula, 13 of 15 (86.7%) in primary pterygia, and 7 of 7 (100%) in recurrent pterygia. High rates of FFs were identified at the head of pinguecula, primary pterygium, recurrent pterygium, and macroscopically normal nasal and temporal limbus. We postulate that FFs may represent precursor lesions to UV-associated ocular surface pathology. Identification of Fuchs fleck by IVCM may permit clinicians to predict the patients who may progress to develop more advanced pathology.
- 1 December 2015
- Published by Wolters Kluwer Health in Cornea
- Vol. 34 (12) , 1560-1563
Significance of Fuchs Flecks in Patients With Pterygium/Pinguecula
Fuchs flecks (FFs) have been previously identified at the leading edge of pterygia and may represent collections of epithelial stem-like cells that give rise to this condition. This study aims to evaluate the clinical significance of FFs in patients with ocular surface disorders, such as pterygium and pinguecula, by in vivo confocal microscopy (IVCM). This study is a Single-center, retrospective, observational case series of 40 eyes from 20 patients with clinical diagnoses of pinguecula or pterygium, or both. IVCM (Rostock Cornea Module; Heidelberg Engineering, Heidelberg, Germany) was performed on patients with pinguecula or pterygium, or both. The presence of FFs on the ocular surface of patients with pterygium and pinguecula was assessed by IVCM and subsequently documented. FFs were present in 24 of 30 eyes (80.0%) in paired macroscopically normal nasal or limbal regions, 19 of 20 (95.0%) in pinguecula, 13 of 15 (86.7%) in primary pterygia, and 7 of 7 (100%) in recurrent pterygia. High rates of FFs were identified at the head of pinguecula, primary pterygium, recurrent pterygium, and macroscopically normal nasal and temporal limbus. We postulate that FFs may represent precursor lesions to UV-associated ocular surface pathology. Identification of Fuchs fleck by IVCM may permit clinicians to predict the patients who may progress to develop more advanced pathology.
- Open Access
- 6 October 2014
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 16 (1) , 59-66
Expression of classical components of the renin-angiotensin system in the human eye
Purpose: The purpose of this study was to determine the relative expression of clinically-relevant components of the renin-angiotensin system (RAS) in the adult human eye. Methods: We obtained 14 post-mortem enucleated human eyes from patients whom had no history of inflammatory ocular disease nor pre-mortem ocular infection. We determined the gene expression for prorenin, renin, prorenin receptor, angiotensin-converting enzyme, angiotensinogen and angiotensin II Type 1 receptor, on tissue sections and in cultured human primary retinal pigment epithelial and iris pigment epithelial (RPE/IPE) cell lines, using both qualitative and quantitative reverse transcription polymerase chain reaction (RT-PCR). Protein expression was studied using indirect immunofluorescence (IF). Results: Almost all components of the classical RAS were found at high levels, at both the transcript and protein level, in the eyes’ uvea and retina; and at lower levels in the cornea, conjunctiva and sclera. There was a much lower level of expression in the reference cultured RPE/IPE cells lines. Conclusion: This study describes the distribution of RAS in the normal adult human eye and demonstrates the existence of an independent ocular RAS, with uveal and retinal tissues showing the highest expression of RAS components. These preliminary findings provide scope for examination of additional components of this system in the human eye, as well as possible differential expression under pathological conditions.
- 6 October 2014
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 16 (1) , 59-66
Open AccessExpression of classical components of the renin-angiotensin system in the human eye
Purpose: The purpose of this study was to determine the relative expression of clinically-relevant components of the renin-angiotensin system (RAS) in the adult human eye. Methods: We obtained 14 post-mortem enucleated human eyes from patients whom had no history of inflammatory ocular disease nor pre-mortem ocular infection. We determined the gene expression for prorenin, renin, prorenin receptor, angiotensin-converting enzyme, angiotensinogen and angiotensin II Type 1 receptor, on tissue sections and in cultured human primary retinal pigment epithelial and iris pigment epithelial (RPE/IPE) cell lines, using both qualitative and quantitative reverse transcription polymerase chain reaction (RT-PCR). Protein expression was studied using indirect immunofluorescence (IF). Results: Almost all components of the classical RAS were found at high levels, at both the transcript and protein level, in the eyes’ uvea and retina; and at lower levels in the cornea, conjunctiva and sclera. There was a much lower level of expression in the reference cultured RPE/IPE cells lines. Conclusion: This study describes the distribution of RAS in the normal adult human eye and demonstrates the existence of an independent ocular RAS, with uveal and retinal tissues showing the highest expression of RAS components. These preliminary findings provide scope for examination of additional components of this system in the human eye, as well as possible differential expression under pathological conditions.
- Open Access
- 16 July 2014
- Published by Springer Nature in Journal of Inflammation
- Vol. 11 (1) , 20
Role of toll-like receptors in human iris pigment epithelial cells and their response to pathogen-associated molecular patterns
Toll-like receptor (TLR) activation is hypothesized to contribute to inflammatory eye disease including uveitis, yet the distribution pattern of TLRs in human uveal tissues remains poorly described. The purpose of this study was to investigate the expression profile of TLRs in human iris pigment epithelial cells (IPE) at the gene and protein level and examine the effect of pathogen-associated molecular patterns (PAMPs), such as Pam3CSK4.3HCl, Poly(I:C), lipopolysaccharides (LPS from E. coli serotype O111:B4), Flagellin, MALP-2 (macrophage activating lipopeptide-2), Poly(U) and CpGODN2395 on the production of inflammatory mediators including interleukin-8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) from human IPE and retinal pigment epithelial cells (RPE).
- 16 July 2014
- Published by Springer Nature in Journal of Inflammation
- Vol. 11 (1) , 20
Open AccessRole of toll-like receptors in human iris pigment epithelial cells and their response to pathogen-associated molecular patterns
Toll-like receptor (TLR) activation is hypothesized to contribute to inflammatory eye disease including uveitis, yet the distribution pattern of TLRs in human uveal tissues remains poorly described. The purpose of this study was to investigate the expression profile of TLRs in human iris pigment epithelial cells (IPE) at the gene and protein level and examine the effect of pathogen-associated molecular patterns (PAMPs), such as Pam3CSK4.3HCl, Poly(I:C), lipopolysaccharides (LPS from E. coli serotype O111:B4), Flagellin, MALP-2 (macrophage activating lipopeptide-2), Poly(U) and CpGODN2395 on the production of inflammatory mediators including interleukin-8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) from human IPE and retinal pigment epithelial cells (RPE).
- 4 October 2013
- Published by IOP Publishing in Journal of Breath Research
- Vol. 7 (4) , 046003
Measurement of neopterin, TGF-β1and ACE in the exhaled breath condensate of patients with sarcoidosis
Exhaled breath condensate (EBC) is a non-invasive method of sampling airway lining fluids in respiratory diseases. This may be useful in identifying exhaled biomarkers of granulomatous inflammation and pulmonary fibrosis in patients with sarcoidosis. The aim of this pilot study was to identify markers of granulomatous airway inflammation and disease activity including neopterin, transforming growth factor-β1 (TGF-β1) and angiotensin converting enzyme (ACE) in EBC. EBC was collected from 16 patients with sarcoidosis and 22 healthy control subjects. EBC neopterin, and active-TGF-β1 were measured by ELISA. EBC–ACE activity was measured using a colorimetric assay. EBC neopterin was detectable in 3/20 controls and 7/16 patients with sarcoidosis. Patients with sarcoidosis had greater mean neopterin levels compared to control subjects (0.57 ± 0.45 nmol l−1 versus 0.41 ± 0.22 nmol l−1, p = 0.04). TGF-β1 was detectable in the EBC of all subjects and concentrations were higher in patients with sarcoidosis compared with controls (115.5 ± 79.6 pg mol−1 versus 82.3 ± 16.2 pg mol−1, p = 0.048). There was no difference in EBC ACE activity, which was only detectable in 3/20 healthy controls and 2/16 patients (p = 0.91). EBC markers of granulomatous inflammation are detectable at greater levels in patients with sarcoidosis compared to healthy controls subjects. Larger studies and development of sensitive assays are warranted to examine the disease correlates and predictive utility of these markers.
- 4 October 2013
- Published by IOP Publishing in Journal of Breath Research
- Vol. 7 (4) , 046003
Measurement of neopterin, TGF-β1and ACE in the exhaled breath condensate of patients with sarcoidosis
Exhaled breath condensate (EBC) is a non-invasive method of sampling airway lining fluids in respiratory diseases. This may be useful in identifying exhaled biomarkers of granulomatous inflammation and pulmonary fibrosis in patients with sarcoidosis. The aim of this pilot study was to identify markers of granulomatous airway inflammation and disease activity including neopterin, transforming growth factor-β1 (TGF-β1) and angiotensin converting enzyme (ACE) in EBC. EBC was collected from 16 patients with sarcoidosis and 22 healthy control subjects. EBC neopterin, and active-TGF-β1 were measured by ELISA. EBC–ACE activity was measured using a colorimetric assay. EBC neopterin was detectable in 3/20 controls and 7/16 patients with sarcoidosis. Patients with sarcoidosis had greater mean neopterin levels compared to control subjects (0.57 ± 0.45 nmol l−1 versus 0.41 ± 0.22 nmol l−1, p = 0.04). TGF-β1 was detectable in the EBC of all subjects and concentrations were higher in patients with sarcoidosis compared with controls (115.5 ± 79.6 pg mol−1 versus 82.3 ± 16.2 pg mol−1, p = 0.048). There was no difference in EBC ACE activity, which was only detectable in 3/20 healthy controls and 2/16 patients (p = 0.91). EBC markers of granulomatous inflammation are detectable at greater levels in patients with sarcoidosis compared to healthy controls subjects. Larger studies and development of sensitive assays are warranted to examine the disease correlates and predictive utility of these markers.
- Open Access
- 1 May 2013
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 131 (5) , 694-696
Management of Fingolimod-Associated Macular Edema
Fingolimod is the first orally active drug approved for the management of relapsing-remitting multiple sclerosis (MS).1 Its immunosuppressive action is related to downregulation of sphingosine 1–phosphate receptor 1 on lymphocytes, which inhibits their egress from lymphoid tissues.2 Macular edema (ME) is an infrequent adverse effect of fingolimod, usually occurring within 3 months of initiation of treatment and resolving on cessation of fingolimod.1 We report a case of ME in a patient with MS receiving fingolimod and its successful management by topical anti-inflammatory drugs.
- 1 May 2013
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 131 (5) , 694-696
Open AccessManagement of Fingolimod-Associated Macular Edema
Fingolimod is the first orally active drug approved for the management of relapsing-remitting multiple sclerosis (MS).1 Its immunosuppressive action is related to downregulation of sphingosine 1–phosphate receptor 1 on lymphocytes, which inhibits their egress from lymphoid tissues.2 Macular edema (ME) is an infrequent adverse effect of fingolimod, usually occurring within 3 months of initiation of treatment and resolving on cessation of fingolimod.1 We report a case of ME in a patient with MS receiving fingolimod and its successful management by topical anti-inflammatory drugs.
- 1 April 2013
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 39 (4) , 656-657
Comparison of macular morphology between femtosecond laser–assisted and traditional cataract surgery
- 1 April 2013
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 39 (4) , 656-657
Comparison of macular morphology between femtosecond laser–assisted and traditional cataract surgery